Our early COVID-19 case study (1) revealed that both ICOS+PD-1+CD4+ TFHs and activated CD38+HLA-DR+ CD4+/CD8+ T cells appeared transiently in patient's blood at 3 days prior to recovery, suggesting involvement of T cells in the resolution of COVID-19. The gene discussed is CD8A; the disease is COVID-19.